Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Robustness aspects of Continuous Direct Compressed HPMC based Extended Release Tablets

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Presentation
  • By: ABRAHMSéN-ALAMI, Susanna (AstraZeneca, Pharmaceutical Technology and Development, Mölndal, Sweden)
  • Co-author(s): Satu Lakio: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
    Pirjo Tajarobi: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
    Håkan Wikström: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
    Magnus Fransson: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
    Tuomas Ervasti: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
    Simo-Pekka Simonaho: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
    Jarkko Ketolainen: School of Pharmacy, University of Eastern Finland, Kuopio, Finland
    Staffan Folestad: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
    Susanna Abrahmsén-Alami: Pharmaceutical Technology and Development, AstraZeneca, Mölndal, Sweden
  • Abstract:

    Backgrounds

    Continuous manufacturing of drug products is an approach to intensify the efficiency of drug production. The ability to provide extended and robust drug release in vivo relies on assuring proper distribution of both drug substance and matrix former.

    Aims

    The aim was to evaluate the combined effect of processing variables and compositional

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses